Abstract
Liver diseases are serious threat to human health. Chimeric antigen receptor (CAR) T cell technology is a kind of adoptive cell therapy technique, which has been developed rapidly in recent years. It has achieved inspiring clinical efficacy and breakthroughs in hematologic malignancies, especially in B cell malignancies, and shed new light for tumor sufferers. Given the known achievements, CAR-T cells for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and liver cancer have shown great potential as well. However, compared with using of CAR-T in hematologic malignancies, the therapeutic application of CAR-T for liver cancer was few and its efficacy was not obvious. Herein, the review focused more on the preclinical and clinical trials of adoptive cell therapy (mainly CAR-T cells) in the treatment of liver disease, and discussed the therapeutic differences between hematologic malignancies and liver cancer. It will give a new insight for researchers to seek new approaches to improve clinical outcomes of CAR-T cell therapy in liver diseases in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
